26 December 2022 | News
Amgen gets rights to research, develop, and commercialise antibody-drug conjugates combining targets selected with LCB’s proprietary ADC platform
Image Credit: shutterstock.com
South Korea-based LegoChem Biosciences, Inc. (LCB) has entered into a research collaboration and license agreement with US-based Amgen, whereby it has granted Amgen rights to research, develop, and commercialise antibody-drug conjugates (ADCs) directed against up to 5 targets selected by Amgen based on LCB’s proprietary ConjuAll ADC technology.
Under the terms of the agreement, LCB is eligible to receive up to $1.25 billion including upfront, development and commercial milestone payments, and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.
The clinical-stage ConjuAll ADC technology platform provides optimised site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs. It overcomes the limitations associated with conventional technologies that produce heterogeneous ADCs with its greater potency, safety and stability, and enables the development ADCs with a wider therapeutic window and improved manufacturability.
The Korean firm has continued to build a robust ADC licensing deal flow with 12 transactions completed with a cumulative deal volume of over $5 billion